VANCOUVER, BC / ACCESSWIRE / January 29, 2016 / Midnight Sun Mining Corp. (TSXV: MMA) (the “Company” or “Midnight Sun”) has completed the third and final tranche of its previously announced non-brokered private placement. In the third tranche, the Company issued 4,045,000 units (the “Units”) at a price of $0.10 per Unit for gross proceeds of $404,500. Each Unit consists of one (1) common share (“Common Share”) in the capital of the Company and one (1) transferable Common Share purchase warrant (“Warrant”). Each Warrant entitles the holder to purchase one Common Share of the Company for a period of twenty-four months from closing, at an exercise price of $0.20.

All securities issued pursuant to the third and final tranche, including the Common Shares underlying the Warrants, are subject to a statutory hold period which expires on May 30, 2016.

In total, the Company issued 6,901,250 Units for gross proceeds of $690,125. Finder’s fees of $13,400 were paid in cash and 134,000 Broker’s Warrants were issued in connection with the Private Placement. Each Broker’s Warrant entitles the holder to purchase one common share at a price of $0.20 for a period of 24 months, expiring on January 29, 2018.

In total, Insiders of the Company purchased 1,570,000 Units for gross proceeds of $157,000.

The net proceeds of the Offering will be used by the Company to fund further exploration work on its optioned Zambian mineral exploration permits as well as general working capital.

The completion of the private placement is subject to final acceptance by the TSX Venture Exchange.

Zambian Update

The Company has retained Blu Rock Mining Services Ltd to conduct a drill campaign of approximately 600-650 metres on the Company’s optioned Solwezi Property. The drill program will test the previously identified (see Company news release dated May 7, 2015) Dumbwa Central soil anomaly and the Mitu targets, which are located approximately 10 kilometres south of the Dumbwa Central target. The Company anticipates results of this program during the first quarter of 2016.

This press release is not an offer or a solicitation of an offer of securities for sale in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration.

ON BEHALF OF THE BOARD

Robert Sibthorpe
President & CEO

For further information contact:

Al Fabbro
Director
Tel: 604-351-8850

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

These securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States or to, or for the benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act) absent U.S. registration or an applicable exemption from the U.S. registration requirements. This release does not constitute an offer for sale of securities in the United States.

This news release includes certain statements that may be deemed “forward-looking statements.” All statements in this release, other than statements of historical facts, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include, changes in market conditions, unsuccessful exploration results, unanticipated changes in key management personnel and general economic conditions. Mining exploration and development is an inherently risky business. Accordingly the actual events may differ materially from those projected in the forward-looking statements. This list is not exhaustive of the factors that may affect any of the Company’s forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on the Company’s forward-looking statements. The Company does not undertake to update any forward-looking statement that may be made from time to time by the Company or on its behalf, except in accordance with applicable securities laws.

NOT FOR DISTRIBUTION TO THE UNITED STATES OR FOR DISSEMINATION IN THE UNITED STATES

SOURCE: Midnight Sun Mining Corp.

ReleaseID: 436193

WINDSOR, ON / ACCESSWIRE / January 29, 2016 / The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, has developed a list of stocks skirting the boundaries of reality which could make a big contribution to healthcare innovation in 2016 and beyond.

We will get into the details below, but first, here is our list:

1) Endonovo Therapeutics, Inc. (OTCQB: ENDV)
2) Second Sight Medical Products, Inc. (NASDAQ: EYES)
3) Corindus Vascular Robotics, Inc. (NYSE MKT: CVRS)
4) Sangamo BioSciences Inc. (NASDAQ: SGMO)

First and foremost Endonovo Therapeutics, Inc. (OTCQB: ENDV) is an innovative biotechnology company developing bioelectronic devices and therapies for regenerative medicine to help those in need. This biotech company has clearly created a technology way ahead of its time set to benefit those in need. In need, meaning, potentially any individual with liver failure, which affects tens of thousands of individuals worldwide. The only potential cure prior to Endonovo’s medical device (pending FDA approval) was a liver transplant, which most would wait on a lengthy list and possibly die before anything could even be done. With technology like this, way ahead of its time, it’s a wonder that large Investors and big pharma have not jumped all over this company.

Endonovo’s Immunotronic technology was originally developed at NASA to treat injury and diseases astronauts may encounter during long-term missions. However, the non-implantable bioelectronic device ENDV has for potentially treating/preventing vital organ failure through the reduction of inflammation and the promotion of regeneration has been designed to be completely safe and non-invasive. Based on approval for safety and effectiveness, this could be a potential paradigm shift for all those suffering from failing organs, to be first shown on the human liver.

Endonovo’s other device, the Cytotronic platform, provides for a method of expanding and enhancing cells using simulated microgravity and Time-Varying Electromagnetic Fields (TVEMF) for cell therapies which the company intends to utilize in the treatment of graft versus host disease.

The company has developed a different type of science. A science some may call futuristic because of its healing capabilities. Only a few years ago, the only treatment for liver disease was a transplant, now ENDV has stepped into the picture and could change this world as we know it.

Second Sight Medical Products, Inc. (NASDAQ:EYES) is truly a remarkable company with its mission is to develop, manufacture and market innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Who would have ever thought the blind could have a chance to see again? Not many. This type of technology is beyond unique– Some may even call it futuristic.

EYES’s technology is not for all blind people, but for the individuals who lost their vision due to retinitis pigmentosa (RP) which severely damages the photoreceptors in our eyes. Second Sight has already developed and has started manufacturing the Argus(R) II Retinal Prosthesis System. Enrollment is underway in a trial to test the safety and utility of the Argus II in individuals with Dry Age-Related Macular Degeneration as a second indication for treatment. Second Sight is also developing the Orion(TM) I Visual Cortical Prosthesis to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions. Science such as this is mind blowing, and this company is doing everything in its powers to help individuals see again. Most who go blind, for whatever the reason, tend to lose hope, but with companies such as EYES around, we believe hope should not be lost.

Corindus Vascular Robotics Inc. (NYSE MKT:CVRS) is a global technology leader in robotic-assisted percutaneous coronary interventions (PCIs), a non-surgical procedure that uses a catheter (a thin flexible tube) to place a small structure called a stent to open up blood vessels in the heart that have been narrowed by plaque buildup.

The company’s CorPath System is the first system that is actually FDA-cleared. This medical device called a CorPath system is the first of its kind that offers interventional cardiologists PCI, a procedure control from a radiation protective interventional cockpit. The occupational hazards in the cath lab are extremely serious due to radiation. As the PCI procedures became more complex and longer, so did radiation exposure and time in heavy led gear. However, with science on their side, Corindus developed the much talked about CorPath system to bring robotic precision to interventional cardiology. Doing all this while enabling a safer work environment for the cath lab team. The benefits of the CorPath Robotic-Assisted PCI are tremendous in results: First of all, there is a 95% reduction in radiation exposure alone for the primary operator. Also, they are now able to perform procedures much more safely and comfortably, while being seated without all the heavy radiation gear. The list of positives goes on and on and the fact that it’s FDA-cleared should be a clear sign to investors all over that potential revenue growth could accelerate.

Sangamo BioSciences (NASDAQ:SGMO) Inc. is focused on engineering genetic cures for monogenic and infectious diseases by deploying its novel DNA-binding protein technology. Gene-Editing isn’t simple; it requires the smartest of individuals to be in the field working countless hours to solve the codes of the complex human body to “edit out/ edit in” certain problem/ solution genes linked to disease.

This scientific gene-editing company has a pipeline of therapies it is developing with no clear (publically traded) competitors in sight. With the much anticipated IPO of Editas, a gene editing biotech with big Investor names behind it, 2016 may see a lot of the hot/ momentum money flow into this niche of biotech.

They are already in clinic with phase 2 trials for their HIV/ AIDS (T-Cell), Phase 1 of their HIV / AIDS (Stem Cell), Phase 1 of Hemophilia B, and numerous of other diseases that they are working on. Quite the pipeline. This companys strategy is to develop their ZFP technology through research, preclinical and early stage clinical testing. After proof of concept and early positive clinical data, they will look to partner or license a part of their technology to larger players in the biotech arena.

Based on the predicted money-flow into this space by the financial pundits and Wall Street as a whole, this name should at the very least be watch-listed starting from the time Editas prices their IPO (symbol to be EDIT), as strong trading for them out of the gate may re-ignite the whole biotech complex and supercharge those in the gene editing space.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Text Message Alerts, Twitter and Facebook.

GET BREAKING NEWS FROM US:

Email us with questions: Info@WealthyVentureCapitalist.com

To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z

Follow us on Twitter: @Wealthy_VC

Like us on Facebook: www.facebook.com/WealthyVC

This report/release/profile is a commercial advertisement and is for general information and entertainment purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

The Wealthy Biotech Trader’s controlling parent company has been compensated $150,000 by Endonovo Therapeutics, Inc. in the form of a convertible note and readers should understand that they will convert this note into common shares sell them into the market as soon as the statutory 144 hold period has lapsed.

Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

SOURCE: The Wealthy Venture Capitalist

ReleaseID: 436195

TORONTO, ON / ACCESSWIRE / January 29, 2016 / DNI Metals Inc. (CSE: DNI) (“DNI” or the “Company”) announces that, further to its news release dated January 29, 2016, the Company has closed, subject to final Regulatory approval, the first tranche (the “First Tranche”) of its non-brokered private placement financing (the “Private Placement”). The First Tranche comprises 2,000,000 units of the Company (the “Units”) at a price of CDN$0.05 per Unit for aggregate gross proceeds of CDN$100,000. Each Unit consists of one common share of the Company (a “Common Share”) and one common share purchase warrant of the Company (“Warrant”). Each Warrant will entitle the holder to acquire one additional Common Share at a price of CDN$0.10 per Common Share for a period of 18 months following the date of the closing of the First Tranche. All securities issued under the First Tranche are subject to a four month hold period expiring on May 29th 2016. Pursuant to this placement, DNI’s officers and directors subscribed for 70.5% of the securities in the first tranche of the Private Placement.

An aggregate cash commission of $8,000, plus an aggregate of 160,000 non-transferable common share purchase warrants (the “Finder’s Warrants”) is, subject to final Regulatory approval, payable in connection with the closing of the First Tranche to Industrial Alliance Financial Group. Each Finder’s Warrant will be exercisable into one Common Share at an exercise price of CDN$.10 for a period of 18 months following issuance.

The Company expects to use the proceeds raised from the First Tranche to fund general and operating working capital.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

DNI – Canadian Securities Exchange
DG7N – Frankfurt
Issued: 29,586,204

For further information, contact:

DNI Metals Inc. – Dan Weir, President & CEO 416-595-1195
DanWeir@dnimetals.com

Email ir@dnimetals.com. Also visit www.dnimetals.com

Katrin Tosine
Capital Markets and Investor Relations Advisor
kat@dnimetals.com
647.388.4984

We seek Safe Harbour. This announcement includes forward looking statements. While these statements represent DNI’s best current judgment, they are subject to risks and uncertainties that could cause actual results to vary, including risk factors listed in DNI’s Annual Information Form and its MD&As, all of which are available from SEDAR and on its website.

Caution Regarding Forward-Looking Information

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the anticipated benefits of the Transaction to the Company and shareholders of the Company; the pro forma shareholdings of the Company’s shareholders in DNI; execution of the Definitive Agreement, the timing and receipt of the required shareholder, stock exchange and regulatory approvals for the Transaction; the anticipated timing for mailing the management information circular to the shareholders of the Company in respect of the Transaction; the closing of the Transaction; the length of the current market cycle and requirements for an issuer to survive in the current market cycle; future growth potential of DNI and its business; and future mine development plans.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: satisfaction or waiver of all applicable conditions to closing of the Transaction (including receipt of all necessary shareholder, stock exchange and regulatory approvals or consents, and the absence of material changes with respect to the parties and their respective businesses); the synergies expected from the Transaction not being realized; business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets and the market price of the DNI Shares and the Company Shares; fluctuations in spot and forward prices of graphite or certain other commodities; fluctuations in currency markets (such as the Canadian dollar to United States dollar exchange rate); change in national and local government, legislation, taxation, controls, regulations and political or economic developments; risks and hazards associated with the business of mineral exploration, development and mining (including environmental hazards, industrial accidents, unusual or unexpected formations pressures, cave-ins and flooding); inability to obtain adequate insurance to cover risks and hazards; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); and title to properties. In addition, the failure of a party to comply with the terms of the Definitive Agreement (assuming the Definitive Agreement is entered into) may result in that party being required to pay a non–completion or other fee to the other party, the result of which could have a material adverse effect on the paying party’s financial position and results of operations and its ability to fund growth prospects and current operations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended.

Readers should not place undue reliance on the forward–looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward–looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

SOURCE: DNI Metals Inc.

ReleaseID: 436197